1476847-69-4

Upstream product

• 1476847-70-7 2-methoxy-6-(6-methoxy-4-(prop-2-yn-1-yloxy)benzofuran-2-yl)imidazo[2,1-b][1,3,4]thiadiazole 
• 622-37-7 Phenyl azide 
• 1476847-52-5 1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone 
• 1476847-54-7 6-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoimidazo[2,1-b][1,3,4]thiadiazole 
• 1476847-55-8 6-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-b][1,3,4]thiadiazole 
• 1476847-56-9 6-methoxy-2-(2-methoxyimidazolo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-ol 
• 62-53-3 aniline 

Relevant academic research and scientific papers

PAR4 AGONIST PEPTIDES

The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.